KS has received per diem, including speaking fees, from Novartis Pharma, Takeda Pharmaceuticals, and Meiji Seika Pharma; has received research funding from EPS International, AbbVie, PharmaEssentia Japan, AstraZeneca, and Kowa; and has received scholarship or grant donations from Chugai Pharmaceutical, AbbVie, the Shinnihon Foundation of Advanced Medical Treatment Research, the Japanese Society of Hematology, Life Science Foundation of Japan, and Setsuro Fujii Memorial Osaka Foundation for Promotion of Fundamental Medical Research. NT has received per diem, including speaking fees, from Pfizer, Novartis Pharma, and Otsuka Pharmaceutical; has received research funding from Pfizer, Novartis Pharma, Otsuka Pharmaceutical, and Astellas Pharma; and has received scholarship or grant donations from Astellas Pharma, Mochida Pharmaceutical, Asahi Kasei Pharma, and Otsuka Pharmaceutical. NI has received per diem, including speaking fees, from Bristol Myers Squibb and Novartis Pharma. TK has received per diem, including speaking fees, from Alexion Pharmaceuticals. SK has received per diem, including speaking fees, from Bristol Myers Squibb, Pfizer, Novartis Pharma, and Otsuka Pharmaceutical; has received research funding from Ohara Pharmaceutical, Bristol Myers Squibb, and Pfizer; and has received scholarship or grant donations from Chugai Pharmaceutical, Kyowa Kirin, Taiho Pharmaceutical, Nippon Kayaku, Takeda Pharmaceuticals, Asahi Kasei Phama, Daiichi Sankyo, Mochida Pharmaceutical, and Otsuka Pharmaceutical. KK has received per diem, including speaking fees, from Takeda Pharmaceuticals. KT has received per diem, including speaking fees, from Novartis Pharma, MSD, Kyowa Kirin, Takeda Pharmaceuticals, Janssen Pharmaceutical, Otsuka Pharmaceutical, Astellas Pharma, Ono Pharmaceutical, Chugai Pharmaceutical, and Bristol Myers Squibb and has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Otsuka Pharmaceutical, Asahi Kasei Phama, Daiichi Sankyo, and Japan Blood Products Organization.